• / Free eNewsletters & Magazine
  • / My Account
Home>Sunovion to buy Cynapsus Therapeuticals for 120% premium

Sunovion to buy Cynapsus Therapeuticals for 120% premium

3party Content

Wed, 31 Aug 2016

Sunovion Pharmaceuticals Inc. said late Wednesday it has agreed to buy Cynapsus Therapeuticals Inc. (CTH.T) for $40.50 a share in an all-cash deal that values the Toronto-based Cynapsus at $624 million and represents a 120% premium over Cynapsus' close of $18.36 on Wednesday. Both companies' board
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.